drugset
drugset / Trial / NCT00744562

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

NCT00744562 ↗

Phase 1 Completed 42 enrolled OncoMed Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated solid tumour for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.

Timeline

Start
2008-08
Primary completion
2011-11
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Demcizumab Monoclonal antibody 0.5 mg/kg Intravenous
Subject Demcizumab Monoclonal antibody 1 mg/kg Intravenous
Subject Demcizumab Monoclonal antibody 2.5 mg/kg Intravenous
Subject Demcizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Demcizumab Monoclonal antibody 10 mg/kg Intravenous

Indications

cancer